DBT–BIRAC Host 12th Webinar on Cell & Gene Therapy Advancements
Technology

DBT–BIRAC Host 12th Webinar on Cell & Gene Therapy Advancements

The Department of Biotechnology (DBT), Government of India, in collaboration with BIRAC, held the 12th webinar under its Biomanufacturing and Biofoundry Initiative on 17th April 2025. Themed around “Cell and Gene Therapy”, the session falls under the Precision Biotherapeutics focus of the BioE3 (Biotechnology for Economy, Environment & Employment) Policy, which was approved by the Union Cabinet in August 2024.

With its transformative potential in treating complex and previously incurable diseases, Cell and Gene Therapy (CGT) is a priority area within the BioE3 vision to position India as a global leader in sustainable, high-performance biomanufacturing.

Highlights from the Webinar Dr Alka Sharma, Senior Adviser, DBT, opened the session by reiterating the BioE3 Policy’s mission to support green, high-impact biomanufacturing. She emphasised the need for strategic interventions to overcome sectoral challenges and drive growth in CGT innovation and accessibility.

Dr Kamakshi Chaithri, Scientist ‘D’, DBT, stressed the urgent need to prioritise this domain, particularly for life-threatening conditions like cancer and rare diseases. She outlined global and national positioning and underlined the DBT’s ongoing efforts to build a conducive innovation ecosystem for indigenous CGT development.

Dr Debojyoti Chakraborty, Principal Scientist at CSIR–IGIB, discussed cutting-edge gene editing technologies targeting sickle cell anaemia, ocular disorders, and more. He noted the regulatory and manufacturing bottlenecks and the importance of ensuring therapies are affordable and accessible.

Dr Anil Kamat, Head of Clinical Development, Immuneel Therapeutics, spoke on the commercial approval of CAR-T Cell therapy, supported by BIRAC. He discussed scale-up challenges and suggested solutions for improving access, affordability, and availability of CGTs.

The Department of Biotechnology (DBT), Government of India, in collaboration with BIRAC, held the 12th webinar under its Biomanufacturing and Biofoundry Initiative on 17th April 2025. Themed around “Cell and Gene Therapy”, the session falls under the Precision Biotherapeutics focus of the BioE3 (Biotechnology for Economy, Environment & Employment) Policy, which was approved by the Union Cabinet in August 2024. With its transformative potential in treating complex and previously incurable diseases, Cell and Gene Therapy (CGT) is a priority area within the BioE3 vision to position India as a global leader in sustainable, high-performance biomanufacturing. Highlights from the Webinar Dr Alka Sharma, Senior Adviser, DBT, opened the session by reiterating the BioE3 Policy’s mission to support green, high-impact biomanufacturing. She emphasised the need for strategic interventions to overcome sectoral challenges and drive growth in CGT innovation and accessibility. Dr Kamakshi Chaithri, Scientist ‘D’, DBT, stressed the urgent need to prioritise this domain, particularly for life-threatening conditions like cancer and rare diseases. She outlined global and national positioning and underlined the DBT’s ongoing efforts to build a conducive innovation ecosystem for indigenous CGT development. Dr Debojyoti Chakraborty, Principal Scientist at CSIR–IGIB, discussed cutting-edge gene editing technologies targeting sickle cell anaemia, ocular disorders, and more. He noted the regulatory and manufacturing bottlenecks and the importance of ensuring therapies are affordable and accessible. Dr Anil Kamat, Head of Clinical Development, Immuneel Therapeutics, spoke on the commercial approval of CAR-T Cell therapy, supported by BIRAC. He discussed scale-up challenges and suggested solutions for improving access, affordability, and availability of CGTs.

Next Story
Infrastructure Urban

Arya Omnitalk Powers India’s Toll Revolution with AI-Driven Solutions

Arya Omnitalk, a leader in intelligent transportation systems, is revolutionising toll collection across India’s national highways with its advanced AI-powered Toll Management Solutions. Designed for rugged remote toll locations, the company’s cutting-edge technology ensures seamless, reliable, and secure tolling—especially during high-capacity operations exceeding 200%. By integrating real-time analytics, cyber protection, and FASTag-based cashless tolling, Arya Omnitalk’s systems are significantly reducing congestion, improving transparency, and enhancing revenue assurance. Its full..

Next Story
Infrastructure Urban

Over 800 Join Anant Raj Runathon to Mark Earth Day

Over 800 participants came together at Anant Raj Estate, Sector 63A, Gurugram, for the Anant Raj Runathon 2025—a vibrant celebration of Earth Day through fitness, community bonding, and sustainability. Curated by renowned running coach Ravinder, the event featured four categories: 10-mile and 5-mile timed runs, a 5-mile walkathon, and a 1-mile kids’ run. Runners of all ages took to the green, scenic roads of the area—some chasing personal bests, others running for a cause. The Runathon was designed to promote healthy living while raising awareness about sustainable practices. Participa..

Next Story
Infrastructure Urban

PETRONAS Lubricants, Quaker Houghton Ink Strategic Deal

In a significant step towards strengthening industrial operations in India and Malaysia, PETRONAS Lubricants India Pvt. Ltd (PLIPL) and Quaker Houghton have announced a strategic partnership aimed at delivering high-performance industrial fluid solutions to key manufacturing sectors, including steel production. The collaboration combines the strengths of both companies—leveraging PETRONAS Lubricants India’s maintenance lubricant technologies and Quaker Houghton’s deep expertise in metalworking fluids. Starting from the second quarter of 2025, Quaker Houghton will begin offering PETRONAS..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?